Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

Table 1

Eculizumab doses administered to patient 1 and analytical data after the corresponding eculizumab administration.

Phase	Week: dose number	ECU; IV (mg)	Platelets; (number/μL)	LDH; (IU/L)	Hemoglobin; (mg/dL)	Haptoglobin; (mg/dL)	Schistocytes	Serum creatinine; (mg/dL)
Initiation	1: 1	900	68,000	1,270	7.5	<7.6	—	5.3
	2: 2	900	144,000	1,119	10.5	—	—	3.1
	3: 3	900	214,000	1,269	9.8	—	—	5.2
	4: 4	900	141,000	1,135	9.2	<7.4	—	4.0
Maintenance	5: 5	1,200	104,000	—	8.5	<7.4	—	2.9
	7: 6	1,200	52,000	1,092	9.6	<7.4	6 in 10 fields	2.8
	9: 7	1,500	62,000	1,099	8.0	<7.4	—	2.1
	11: 8	1,200	85,000	1,037	9.3	<7.4	—	2.1
	13: 9	1,200	283,000	534	7.4	80	—	2.1
	15: 10	1,200	209,000	389	11.3	140	0	3.5
	17: 11	1,200	188,000	342	11.4	91.4	—	2.4

The modified eculizumab dosage pattern is highlighted in bold: the 7th dose of eculizumab was increased from 1,200 mg to 1,500 mg. Also, it was administered 12 days after the 6th (2 days earlier than scheduled according to the center’s protocol).
ECU: eculizumab; LDH: lactate dehydrogenase.